Skip to main content
. 2020 May 28;182(2):451–463. doi: 10.1007/s10549-020-05702-6

Fig. 4.

Fig. 4

Relative abundance levels (mean, median, minimum and maximum) of Firmicutes by four groups of breast cancer patients are shown: HER2− breast cancer and later age at menarche (≥ 12) (n = 18), HER2+ breast cancer and late age at menarche (n = 8), HER− breast cancer and early age at menarche (≤ 11) (n = 7), and HER2+ breast cancer and early age at menarche (n = 4)